Tokai Pharma initiates late-stage study of galeterone in prostate cancer
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 9:54AM CDT
MDVN: 106.81 (-2.19), TKAI: 13.69 (+0.97), QGEN: 25.73 (+1.00)
Vical's Genital Herpes Vaccine Fails in Phase I/II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 23, 2:55PM CDT
Vical Incorporated (VICL) announced disappointing top-line data from a phase I/II study on its investigational genital herpes vaccine.
VICL: 0.70 (unch), GILD: 113.74 (+0.38), ACOR: 34.07 (+0.65)
Roche to Develop Diagnostic Test for Cardiovascular Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 09, 9:00AM CDT
Roche Holding Ag (RHHBY) announced that it has entered into an agreement to develop a companion diagnostic (CDx) test for DalCor Pharmaceuticals' dalcetrapib.
VRX: 232.32 (+8.93), GILD: 113.74 (+0.38)
Astellas Pharma completes enrollment in CMV vaccine trial
Seeking Alpha - at Seeking Alpha - Thu May 21, 8:59AM CDT
VICL: 0.70 (unch)
Astellas' Myrbetriq for Overactive Bladder Efficient as Add-On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 18, 1:25PM CDT
Astellas Pharma Inc. (ALPMY) announced positive results from a phase IIIb study on Myrbetriq-VESIcare add-on therapy in incontinent overactive bladder patients.
ACT: 298.98 (-2.94), VRX: 232.32 (+8.93)
Chugai Pharma Appears To Own U.S., Japan And EU Patent Rights To Medivation's Xtandi
BioPat Research - at Seeking Alpha - Tue May 12, 10:59AM CDT
MDVN: 106.81 (-2.19), JNJ: 99.53 (+1.13)
Vical Q1 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 11, 1:24PM CDT
Vical Incorporated (VICL) posted a narrower-than-expected loss of 4 cents per share in the first quarter of 2015 driven by a year-over-year surge in revenues.
VICL: 0.70 (unch), ILMN: 219.45 (+2.28), HSP: 89.15 (+0.02)
Medivation (MDVN) Misses on Q1 Earnings, Revenues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri May 08, 2:00PM CDT
Medivation's (MDVN) first quarter results were disappointing with the company missing on both the top and the bottom-lines.
MDVN: 106.81 (-2.19), GILD: 113.74 (+0.38), OSIR: 19.31 (+0.65)
Astellas and Potenza Therapeutics team up in cancer R&D
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 8:54AM CDT
Roche Collaborates with Astellas Pharma for Tissue Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 5:22PM CDT
Roche Holding Ag (RHHBY) announced that its member company, Ventana Medical Systems, Inc. has entered into a master collaboration agreement with Japan-based Astellas Pharma Inc. (ALPMY).
MNK: 122.44 (+2.18), VRX: 232.32 (+8.93)
Merck KGaA-Pfizer to Co-promote Xalkori for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 10:30AM CDT
Merck KGaA (MKGAF) and Pfizer will have signed an agreement to co-promote Xalkori in the U.S., Canada, five countries in the EU, Japan, China and Turkey for lung cancer.
CYTK: 6.10 (+0.02), PFE: 34.36 (+0.50)
Astellas-Medivation's Xtandi Meets Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 3:26PM CDT
Astellas Pharma Inc. (ALPMY) and Medivation announced positive top-line results from the phase II STRIVE study comparing Xtandi to Casodex in CRPC patients.
CYTK: 6.10 (+0.02), MDVN: 106.81 (-2.19), LCI: 59.93 (+2.37)
Xtandi successful in second Phase 2 prostate cancer study
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 7:56AM CDT
MDVN: 106.81 (-2.19)
Vical In-Licenses Antifungal Drug ASP2397 from Astellas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 3:17PM CDT
Vical (VICL) expanded its infectious disease portfolio by acquiring Astellas' (ALPMY) antifungal candidate, ASP2397.
LCI: 59.93 (+2.37), VICL: 0.70 (unch), CBM: 45.61 (+1.91)
Medivation-Astellas' Xtandi Positive in Prostate Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 2:20PM CDT
Medivation, Inc. (MDVN) and Astellas Pharma jointly announced new data from a randomized, double-blind phase II study (TERRAIN) on Xtandi.
CYTK: 6.10 (+0.02), MDVN: 106.81 (-2.19), AZN: 66.45 (+1.90)
Xtandi beats bicalutamide in Phase 2 CRPC trial
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 8:28AM CDT
MDVN: 106.81 (-2.19)
Amgen Seeks Approval for PCSK9 Inhibitor Repatha in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 5:12PM CDT
Amgen (AMGN) submits regulatory application for its cholesterol-lowering candidate, Repatha, in Japan.
LCI: 59.93 (+2.37), CBM: 45.61 (+1.91), AMGN: 154.10 (+2.79)
Best One-Drug Wonder Stock for 2015
Brian Orelli, Keith Speights, and George Budwell, The Motley Fool - Motley Fool - Sun Mar 22, 6:01AM CDT
If a biotech wants to become the next drugmaker with multiple blockbusters on the market, it has to start at the bottom with a single drug. We asked our biotech experts for their top picks for companies with just a single drug on the market. Read...
MDVN: 106.81 (-2.19), OREX: 4.70 (+0.04), ISIS: 53.50 (+0.42)
Amgen JV submits regulatory application in Japan for cholesterol med
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 8:59AM CDT
AMGN: 154.10 (+2.79)
United Therapeutics' High-Risk Cancer Drug Wins FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 4:40PM CDT
United Therapeutics' (UTHR) cancer drug Unituxin gained FDA approval plus a priority review voucher for the treatment of pediatric patients suffering from high-risk neuroblastoma.
LCI: 59.93 (+2.37), UTHR: 171.57 (+3.88), SLXP: 172.96 (+0.15)